Full Breakdown
Nabsys and Hitachi Showcase Electronic Genome Mapping at JSHG 2025
12/18/2025, 10:54:30 AM
Presentation of Advanced Genome Mapping Technology
On December 18, 2025, Nabsys 2.0, LLC, in collaboration with Hitachi High-Tech Corporation, presented groundbreaking data on their electronic genome mapping (EGM) technology at the Japanese Society of Human Genetics (JSHG) Annual Meeting in Yokohama, Japan. The event, running from December 17-20, 2025, featured a luncheon seminar hosted by Dr. Catherine Brownstein from Boston Children’s Hospital, alongside key speakers including Dr. Tadashi Kaname from the National Center for Health and Development and Edd Lee, Global Vice President of Sales and Marketing at Nabsys.
Significance of the OhmX Platform
The data presented highlighted the application of the OhmX Platform in a tertiary children’s hospital, demonstrating its effectiveness in conjunction with a multi-omics strategy to expedite the discovery of genes associated with rare diseases. Dr. Brownstein emphasized the importance of Nabsys’ EGM technology, stating that it provides high-resolution analysis of genome-wide structural variations, which is crucial for understanding the etiology of rare and difficult-to-diagnose diseases.
Research Contributions and Findings
In addition to the seminar, Nabsys and Hitachi High-Tech America, Inc. showcased a scientific poster titled “High-Resolution Detection of TP53 Deletions using Electronic Genome Mapping,” presented by Shuk Shukor. This research focused on the efficacy of EGM in cancer genomics, further illustrating the platform's versatility and impact on genomic research.
Official Statements on EGM Technology
Barrett Bready, M.D., founder and CEO of Nabsys, expressed pride in the research presented, stating, “We are pleased to present a breadth of new and important research at this year’s JSHG meeting that elucidates the real-world impact our product, the OhmX Platform, is having on researchers.” He highlighted the significance of speed, accessibility, and accuracy in the study of whole-genome structural variations, asserting that the platform has revolutionized genome mapping.
Broader Implications of EGM Technology
Nabsys aims to enhance genomics through its innovative EGM technology, which integrates precision electronics, nanofluidics, and computational biology. This approach not only expands capabilities in cytogenetics and molecular genetics but also facilitates comprehensive structural variation analysis for laboratories of various sizes. Founded in 2005 and based in Providence, Rhode Island, Nabsys continues to focus on making genomic research more accessible and efficient.
Verbatim Quotes
- “, Boston Children’s Hospital remarked, “Nabsys’ EGM technology, which delivers high resolution analysis of genome-wide structural variation, enabled us with insights into previously undetectable structural variation and has thus become a crucial tool to understand underlying disease etiology of particularly rare or difficult-to-diagnose diseases.” — Dr. Catherine Brownstein, M.P.H., Ph.D., Boston Children’s Hospital
- “We are pleased to present a breadth of new and important research at this year’s JSHG meeting that elucidates the real-world impact our product, the OhmX Platform, is having on researchers,” — Barrett Bready, M.D., Founder and CEO of Nabsys
This presentation at the JSHG 2025 underscores the potential of electronic genome mapping to transform genomic research, particularly in the fields of rare disease and cancer genomics.
